Non-small-cell lung cancer (NSCLC) accounts for more than 85%.[1] Primary NSCLC patients who have double mutations in epithelial growth factor receptor (EGFR) are less common.[2] It has been well acknowledged that NSCLCs containing EGFR kinase domain mutations are especially sensitive to EGFR tyrosine kinase inhibitors (EGFR TKIs).[3] However, it is not clear how NSCLC patients harboring an EGFR double mutation respond to EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.